IL2 and neuroblastoma: A randomized trial has demonstrated that therapy with an anti-GD2 antibody, interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF) and isotretinoin in the maintenance setting improves outcomes of patients with high-risk neuroblastoma (HR-NB) [5].